Global Pharmaceutical R&D Directory 2024: Development Pipeline of Major Companies, Analyzed by Therapeutic Categories and Stages
January 22, 2024 06:13 ET
|
Research and Markets
Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The "Global Pharmaceutical R&D Directory 2024" has been added to ResearchAndMarkets.com's offering.The Global Pharmaceutical R&D Directory provides...
Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split
January 18, 2024 07:45 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
Global Pharmaceuticals Market Analysis and Forecast to 2027, with Company Profiles of Key Market Players Bayer, Novartis ,Pfizer and Johnson & Johnson
January 04, 2024 09:43 ET
|
Research and Markets
Dublin, Jan. 04, 2024 (GLOBE NEWSWIRE) -- The "Global Pharmaceuticals Market Summary, Competitive Analysis and Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.The...
Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine
December 19, 2023 09:00 ET
|
Processa Pharmaceuticals, Inc.
FDA acknowledges that NGC-Cap is a New Chemical Entity given the changes to metabolism and distribution of its major metabolite 5-FU Interim analysis of the NGC-Cap Phase 1b data shows improved...
Rafarma Pharmaceutical news update
November 30, 2023 09:30 ET
|
Rafarma Pharmaceuticals Inc.
Russia, Moscow, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA). The Company is pleased to announce that it has completed the restructuring, accounting and balance sheet...
Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference
November 30, 2023 08:15 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook
November 29, 2023 08:15 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on developing the next...
Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas
November 09, 2023 08:15 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
China Pharmaceutical Market Landscape and Drugs Pipeline Analysis Report 2023: Business Overview, Clinical Pipeline Insight, Preclinical, Phase-I, Phase-II, Phase-III, Preregistration
November 06, 2023 05:03 ET
|
Research and Markets
Dublin, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The "China Pharmaceutical Companies and Drugs Pipeline Insight 2023" drug pipelines has been added to ResearchAndMarkets.com's offering. Chinese...
Global Inhalable Drugs Industry Trends and Competitive Landscape 2023-2027: North America Leads, Asia-Pacific Shows Promise
November 01, 2023 08:23 ET
|
Research and Markets
Dublin, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The "Global Inhalable Drugs Industry Trends and Competitive Landscape 2023-2027" report has been added to ResearchAndMarkets.com's offering.The global...